13F-HR filed by Ally Bridge Group (NY) LLC
Ally Bridge Group (NY) LLC filed this 13F-HR for the quarter ended 2026-09-30, accepted by EDGAR 2026-11-16 21:33:20 UTC, with 18 holding rows worth $76,049,458.
- Accession
- 0001193125-26-463652
- Filer
- CIK 1822947
- Filed
- 2026-11-16
- Accepted by EDGAR
- Ingested
- Source
- EDGAR live feed
13F report for Q3 2026
A holdings report, 18 entries on the cover page, a total value of $76,049,458 stated on the cover page (in dollars after the unit check, H1), rows summing to $76,049,458 with VALUE read as dollars as filed, 13F file number 028-20834. The quarter's positions are built on this report. The resolved quarter.
Other managers
- included managerFan Yu 028-20833
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| DEFINIUM THERAPEUTICS INC | 24477V105 | COM SHS | 400,000 | $15,224,000 | dollars as filed | call |
| ABIVAX SA- | 00370M103 | SPONSORED ADS | 125,000 | $12,377,500 | dollars as filed | call |
| EDGEWISE THERAPEUTICS INC | 28036F105 | COM | 185,430 | $7,528,458 | dollars as filed | |
| PROMIS NEUROSCIENCES INC | 74346M505 | COM SHS | 620,319 | $6,730,461 | dollars as filed | |
| MINERVA NEUROSCIENCES INC | 603380205 | COM NEW | 1,655,500 | $5,545,925 | dollars as filed | |
| AMYLYX PHARMACEUTICALS INC | 03237H101 | COM | 182,000 | $5,296,200 | dollars as filed | |
| SHATTUCK LABS INC | 82024L103 | COMMON STOCK | 625,190 | $4,263,796 | dollars as filed | |
| Obsidian Therapeutics, Inc. | 67448A106 | Common Stock, $0.0001 par value per share | 302,449 | $4,152,625 | dollars as filed | |
| ALUMIS INC | 022307102 | COM | 400,000 | $2,956,000 | dollars as filed | call |
| AN2 THERAPEUTICS INC | 037326105 | COM | 526,315 | $2,799,996 | dollars as filed | |
| EUPRAXIA PHARMACEUTICALS INC | 29842P105 | COM 298736 AL 3 EURONET WORLDWIDE INC NOTE 0.750% 3/1 | 231,122 | $2,103,210 | dollars as filed | |
| COMPASS THERAPEUTICS INC | 20454B104 | COM | 2,000,000 | $2,080,000 | dollars as filed | call |
| AVALO THERAPEUTICS INC | 05338F306 | COMMON STOCK | 134,429 | $2,060,797 | dollars as filed | |
| INVENTIVA SA | 46124U107 | ADS | 227,250 | $838,553 | dollars as filed | |
| VOGENX INC | 92859A106 | COM | 32,701 | $745,256 | dollars as filed | |
| TRAWS PHARMA INC | 68232V884 | COM NEW | 786,236 | $466,867 | dollars as filed | |
| PERSPECTIVE THERAPEUTICS INC | 46489V302 | COMMON STOCK | 163,634 | $449,994 | dollars as filed | |
| ASSEMBLY BIOSCIENCES INC | 045396207 | COMMON STOCK | 18,298 | $429,820 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001193125-26-463652 | this filing | 2026-11-16 |